Detailed Information

Cited 0 time in webofscience Cited 6 time in scopus
Metadata Downloads

Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B

Authors
Kang, Seong HeeYim, Hyung JoonKim, Hae RimKang, KeunheeSuh, Sang JunLee, Hyun JungYoon, Eileen L.Kim, Ji HoonSeo, Yeon SeokYeon, Jong EunByun, Kwan Soo
Issue Date
Nov-2014
Publisher
Lippincott Williams and Wilkins
Keywords
Adefovir; Chronic hepatitis B; Entecavir; Lamivudine; Resistance
Citation
Journal of Clinical Gastroenterology, v.48, no.10, pp.889 - 895
Indexed
SCIE
SCOPUS
Journal Title
Journal of Clinical Gastroenterology
Volume
48
Number
10
Start Page
889
End Page
895
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/9835
DOI
10.1097/mcg.0000000000000066
ISSN
0192-0790
Abstract
Background and Goals: Data regarding the management of adefovir (ADV) resistance are still limited. The aim of this study is to investigate treatment outcomes of rescue therapy in ADV-resistant chronic hepatitis B (CHB) patients. Study: CHB patients who began rescue therapy due to documented genotypic resistance mutations to ADV between October 2006 and July 2012 were retrospectively reviewed. Results: Sixty-three patients were included in this study. Most patients had history of lamivudine (LAM) resistance. Treatment response was evaluated at 3-month intervals up to 12 months. The cumulative rate of complete virologic response (CVR) in hepatitis B virus (HBV)-infected patients (HBV DNA<60 IU/mL) was 15.9%, 27.2%, 28.9%, and 31.7% after 3, 6, 9, and 12 months of rescue therapy. Thirty-five patients were treated with a combination of LAM plus ADV (LAM+ADV group) and 28 patients were treated with entecavir (ETV)-based therapy (ETV with or without ADV therapy, ETV±ADV group). The cumulative CVR rate was significantly higher in the ETV±ADV group than in the LAM+ADV group at month 12 (46.4% vs. 20.6%, respectively, P=0.040). Multivariate analysis showed that pretreatment serum HBV DNA levels at <6 log10 IU/mL (hazard ratio: 34.109, P=0.001) and type of rescue therapy (hazard ratio: 4.944, P=0.036) were associated with CVR. Conclusions: Lower baseline HBV DNA level and ETV±ADV therapy were the important predictive factors for CVR in ADV-resistant CHB patients. This study suggests the need of early switching to a rescue therapy such as ETV±ADV at the time of low-level viremia.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Seo, Yeon Seok photo

Seo, Yeon Seok
Anam Hospital (Department of Gastroenterology and Hepatology, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE